Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

VYGR stock hub

Voyager Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

VYGRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

244.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

VYGR

In the news

Latest news · VYGR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-52.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-240.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All VYGR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001640266
Company name	Voyager Therapeutics, Inc.
Country	United States
Country code	US
Cusip	92915B106
Employees	141
Employees Change	-31%
Employees Change Percent	-18.02
Enterprise value	$107.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-11-11
Isin	US92915B1061
Last refreshed	2026-05-10
Market cap	$244.7M
Market cap category	Micro-Cap
Price	$4.05
Price currency	USD
Rev Per Employee	258,822.7x
Sector	Healthcare
Sic	2836
Symbol	VYGR
Website	https://www.voyagertherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-47.66%
EV Sales Forward	2.26x
EV/Sales	2.95x
FCF yield	-53.1%
P/B ratio	1.22x
P/S ratio	6.71x
PS Forward	5.14x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-243.48%
Gross Profit	$-88.9M
Net Income	$-116.6M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-319.27%
Profit Per Employee	$-827,213
ROA	-27.05
Roa5y	-8.99
ROCE	-61.39
ROE	-52.26
Roe5y	-20.05
ROIC	-240.9

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-10.41%
Cagr1y	23.49%
Cagr3y	-20.49%
Cagr5y	-1.24%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	-45.5x
Revenue Growth Q	-59.94x
Revenue Growth Years	0x
Revenue Growth3 Y	-42.38x
Revenue Growth5 Y	-25.55x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.13
Assets	$219.3M
Cash	$141.5M
Current Assets	$147M
Current Liabilities	$17.5M
Debt	$34.6M
Debt Equity	$0.2
Equity	$173.7M
Liabilities	$45.7M
Long Term Assets	$72.3M
Long Term Liabilities	$28.2M
Net Cash	$137.1M
Net Cash By Market Cap	$56.02
Net Cash Growth	-45.84%
Net Debt Equity	$-0.79
Tangible Book Value	$173.7M
Tangible Book Value Per Share	$2.88
WACC	9.8

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.42
Net Working Capital	$-4.6M
Quick ratio	8.2
Working Capital	$129.5M
Working Capital Turnover	$0.22

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.73%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-66.67%
1Y total return	23.48%
200-day SMA	4.05
3Y total return	-49.75%
50-day SMA	4.02
50-day SMA vs 200-day SMA	50under200
5Y total return	-6.03%
All Time High	31.91
All Time High Change	-87.31%
All Time High Date	2018-03-05
All Time Low	2.46
All Time Low Change	64.63%
All Time Low Date	2021-10-05
ATR	0.22
Beta	1.26
Beta1y	1
Beta2y	1.18
Ch YTD	3.05
High	4.27
High52	5.55
High52 Date	2025-10-16
High52ch	-27.03%
Low	3.92
Low52	2.65
Low52 Date	2025-05-30
Low52ch	53.12%
Ma50ch	0.67%
Price vs 200-day SMA	0.12%
RSI	53.77
RSI Monthly	44.13
RSI Weekly	51.19
Sharpe ratio	0.58x
Sortino ratio	1.04
Total Return	-1.73%
Tr YTD	3.05
Tr1m	2.27%
Tr1w	7.71%
Tr3m	10.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Price Target Top	$25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.54
Earnings Revenue Estimate	9,026,400x
Earnings Revenue Estimate Growth	39.45x
Operating Income	$-123.9M
Operating margin	-339.6
Price target	$16.5
Price Target Change	$307
Price Target Change Top	$517

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	39,771,143%
Float Percent	65.82%
Shares Insiders	1.09%
Shares Institutions	39.99%
Shares Out	60,421,287
Shares Qo Q	0.95%
Shares Yo Y	1.73%
Short Float	8.97%
Short Ratio	5.45
Short Shares	5.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-143.5M
Average Volume	481,641.4x
Bv Per Share	2.88
CAPEX	$-2M
Ch10y	-66.67
Ch1m	2.27
Ch1w	7.71
Ch1y	23.48
Ch3m	10.05
Ch3y	-49.75
Ch5y	-6.03
Ch6m	-4.26
Change	2.27%
Change From Open	3.32
Close	3.96
Days Gap	-1.01
Depreciation Amortization	3,978,000
Dollar Volume	2,590,728.3
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-123.9M
EBITDA	$-119.9M
EPS	$-1.98
F Score	1
FCF	$-129.9M
FCF EV Yield	-120.75x
FCF Per Share	$-2.15
Financing CF	4,066,000
Fiscal Year End	December
Founded	2,013
Income Tax	$121,000
Investing CF	92,346,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-09
Ma150	4.13
Ma150ch	-2.03%
Ma20	3.94
Ma20ch	2.74%
Net CF	-31,579,000
Next Earnings Date	2026-08-05
Open	3.92
Optionable	Yes
Position In Range	37.68
Post Close	4.05
Postmarket Change Percent	-0.65
Postmarket Price	$4.02
Ppne	39,427,000
Price Date	2026-05-08
Ptbv Ratio	1.41
Relative Volume	1.33x
Revenue	36,494,000x
SBC By Revenue	37.27x
Share Based Comp	13,602,000
Tax By Revenue	0.33x
Tr6m	-4.26%
Us State	Massachusetts
Volume	639,686
Z Score	-1.23

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does VYGR pay a dividend?

Capital-return profile for this ticker.

Performance

VYGR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns VYGR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+40.0%

Float: +65.8% of shares outstanding

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

VYGR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.8

Neutral momentum band

Price vs 200-day MA

+0.1%

50/200-day relationship not available

Beta (5Y)

1.26

More volatile than the market

Sharpe ratio

0.58

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About VYGR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current VYGR stock rating?

Voyager Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VYGR analysis?

The full report lives at /stocks/VYGR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for VYGR?

The latest report frames VYGR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the VYGR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.